Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

vTv Therapeutics (VTVT) Consolidated Net Income (2016 - 2025)

Historic Consolidated Net Income for vTv Therapeutics (VTVT) over the last 12 years, with Q3 2025 value amounting to -$10.3 million.

  • vTv Therapeutics' Consolidated Net Income fell 7714.04% to -$10.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$28.4 million, marking a year-over-year decrease of 2496.81%. This contributed to the annual value of -$22.7 million for FY2024, which is 1255.87% up from last year.
  • vTv Therapeutics' Consolidated Net Income amounted to -$10.3 million in Q3 2025, which was down 7714.04% from -$7.4 million recorded in Q2 2025.
  • vTv Therapeutics' Consolidated Net Income's 5-year high stood at -$841000.0 during Q2 2021, with a 5-year trough of -$10.3 million in Q3 2025.
  • Over the past 5 years, vTv Therapeutics' median Consolidated Net Income value was -$6.0 million (recorded in 2024), while the average stood at -$6.1 million.
  • Over the last 5 years, vTv Therapeutics' Consolidated Net Income had its largest YoY gain of 8314.97% in 2021, and its largest YoY loss of 69010.58% in 2021.
  • vTv Therapeutics' Consolidated Net Income (Quarter) stood at -$9.5 million in 2021, then soared by 35.78% to -$6.1 million in 2022, then grew by 27.08% to -$4.4 million in 2023, then grew by 0.09% to -$4.4 million in 2024, then tumbled by 133.15% to -$10.3 million in 2025.
  • Its last three reported values are -$10.3 million in Q3 2025, -$7.4 million for Q2 2025, and -$6.2 million during Q1 2025.